Response to letter commenting on: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.

Samuel, Evangeline; Chiang, Cherie; Jennens, Ross; Faulkner, David; Francis, Prudence A

Samuel, Evangeline; Chiang, Cherie; Jennens, Ross; Faulkner, David; Francis, Prudence A.

Afiliação

Samuel E; Department of Medical Oncology, Monash Health, Melbourne, Australia.
Chiang C; Department of Medicine, Peter MacCallum Cancer Center, Melbourne, Australia; Department of Endocrinology and Pathology, Royal Melbourne Hospital, University of Melbourne, Parkville, Australia.
Jennens R; Department of Medical Oncology, Peter MacCallum Cancer Center, Melbourne, Australia.
Faulkner D; Department of Biochemistry, Peter MacCallum Cancer Center, Melbourne, Australia.
Francis PA; Department of Medical Oncology, Peter MacCallum Cancer Center, Melbourne, Australia. Electronic address: prue.francis@petermac.org.

Eur J Cancer ; 136: 206, 2020 09.

Article em En | MEDLINE | ID: mdl-32680789

Assuntos

Neoplasias da Mama; Antineoplásicos Hormonais/uso terapêutico; Neoplasias da Mama/tratamento farmacológico; Estradiol/uso terapêutico; Feminino; Fulvestranto/uso terapêutico; Humanos; Imunoensaio; Pós-Menopausa

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google